Cerebellar ataxia associated with neuroendocrine thymic carcinoma and GAD antibodies.
Bataller
L
L
Valero
C
C
Díaz
R
R
Froufe
A
A
Garcia-Zarza
A
A
Ribalta
T
T
Vilchez
J J
JJ
Saiz
A
A
D001323:Autoantibodies / Q000097:blood*; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D005968:Glutamate Decarboxylase / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology / Q000628:therapy; D009460:Neurologic Examination; D020362:Paraneoplastic Cerebellar Degeneration / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology / Q000628:therapy; D013934:Thymectomy; D013950:Thymus Gland / Q000276:immunology / Q000473:pathology; D013953:Thymus Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology / Q000628:therapy
D001323:Autoantibodies; D005968:Glutamate Decarboxylase